Article tools
Author information

Research Article

The inverse association of plasma lipoprotein(a) concentrations with apolipoprotein(a) isoform size is not due to differences in Lp(a) catabolism but to differences in production rate.

D J Rader, W Cain, K Ikewaki, G Talley, L A Zech, D Usher and H B Brewer, Jr

Molecular Disease Branch National Heart, Lung, and Blood Institute, National Institutes of Health Bethesda, Maryland 20892.

Published June, 1994

Lipoprotein(a) (Lp[a]) is an atherogenic lipoprotein which is similar in structure to low density lipoproteins (LDL) but contains an additional protein called apolipoprotein(a) (apo[a]). Apo(a) is highly polymorphic in size, and there is a strong inverse association between the size of the apo(a) isoform and the plasma concentration of Lp(a). We directly compared the in vivo catabolism of Lp(a) particles containing different size apo(a) isoforms to establish whether there is an effect of apo(a) isoform size on the catabolic rate of Lp(a). In the first series of studies, four normal subjects were injected with radio-labeled S1-Lp(a) and S2-Lp(a) and another four subjects were injected with radiolabeled S2-Lp(a) and S4-Lp(a). No significant differences in fractional catabolic rate were found between Lp(a) particles containing different apo(a) isoforms. To confirm that apo(a) isoform size does not influence the rate of Lp(a) catabolism, three subjects heterozygous for apo(a) were selected for preparative isolation of both Lp(a) particles. The first was a B/S3-apo(a) subject, the second a S4/S6-apo(a) subject, and the third an F/S3-apo(a) subject. From each subject, both Lp(a) particles were preparatively isolated, radiolabeled, and injected into donor subjects and normal volunteers. In all cases, the catabolic rates of the two forms of Lp(a) were not significantly different. In contrast, the allele-specific apo(a) production rates were more than twice as great for the smaller apo(a) isoforms than for the larger apo(a) isoforms. In a total of 17 studies directly comparing Lp(a) particles of different apo(a) isoform size, the mean fractional catabolic rate of the Lp(a) with smaller size apo(a) was 0.329 +/- 0.090 day-1 and of the Lp(a) with the larger size apo(a) 0.306 +/- 0.079 day-1, not significantly different. In summary, the inverse association of plasma Lp(a) concentrations with apo(a) isoform size is not due to differences in the catabolic rates of Lp(a) but rather to differences in Lp(a) production rates.

Browse pages

Click on an image below to see the page. View PDF of the complete article

Articles that cite
this article:

Lipoprotein(a): structural implications for pathophysiology
M. L. Koschinsky, S. M. Marcovina
IJ Clinical & Laboratory Research 27(1):14. [CrossRef]

Study of Apo(a) Length Polymorphism and Lipoprotein(a) Concentrations in Subjects with Single or Double Apo(a) Isoforms
Mariam Alaoui, Corinne Merle, Roselyne Garnotel, Damien Jolly, Vincent Durlach, Philippe Gillery
cclm 41(5):634. [CrossRef]

Associations Among Serum Lipoprotein(a) Levels, Apolipoprotein(a) Phenotypes, and Myocardial Infarction in Patients With Extremely Low and High Levels of Serum Lipoprotein(a)
Keijiro Saku, Bo Zhang, Rui Liu, Kazuyuki Shirai, Kikuo Arakawa
Jpn Circ J 63(9):659. [CrossRef]

New risk factors for atherosclerosis in hypertension: focus on the prothrombotic state and lipoprotein(a)
Cristiana Catena, Marileda Novello, Roberta Lapenna, Sara Baroselli, Gianluca Colussi, Elisa Nadalini, Grazia Favret, Alessandro Cavarape, Giorgio Soardo, Leonardo A Sechi
J Hypertens 23(9):1617. [CrossRef]

Lipids and lipoprotein(a) concentrations in Pakistani patients with type 2 diabetes mellitus
S. S. Habib, M. Aslam
Diabetes Obes Metab 6(5):338. [CrossRef]

Lipoprotein (a) in patients with hyperlipidaemia
W. Bartens, D. J. Rader, G. Talley, H. B. BREWER Jr
Eur J Clin Invest 25(9):647. [CrossRef]


Hans Dieplinger, Gerd Utermann
Curr Opin Lipidol 10(3):275. [CrossRef]

THE ROLE OF LIPOPROTEIN(a) IN ATHEROGENESIS AND THROMBOSIS
Katherine A. Hajjar, m.d, Ralph L. Nachman, m.d
Ann Rev Med 47(1):423. [CrossRef]

Hormonal influences on lipoprotein(a) metabolism
R. W. C. Pang, K. S. L. Lam
Diabetes Obes Metab 4(3):156. [CrossRef]

Lipoprotein(a) and apolipoprotein(a) isoforms and proteinuria in patients with moderate renal failure
Leonardo A. Sechi, Laura Zingaro, Cristiana Catena, Antonella Perin, Sergio De marchi, Ettore Bartoli
Kidney Int 56(3):1049. [CrossRef]

Plasma lipoprotein (a) concentrations and apolipoprotein (a) phenotypes in an Aboriginal population from Western Australia
Zuowei Xiong, Mark L Wahlqvist, Beryl Biegler, Nicholas DH Balazs, Paul Van Buynder, Naiyana Wattanapenpaiboon
Asia Pac J Clin Nutr 9(3):235. [CrossRef]

Biogenesis of lipoprotein(a) in human and animal hepatocytes
Eva-Maria Lobentanz, Hans Dieplinger
Eletrophoresis 18(14):2677. [CrossRef]

Homocysteine, lipoprotein(a) and fibrinogen: metabolic risk factors for cardiovascular complications of chronic renal disease
Florian Kronenberg
[CrossRef]

Lipoprotein(a) and Thrombocytes: Potential Mechanisms Underlying Cardiovascular Risk
William Discepolo, Ted Wun, Lars Berglund
Pathophysiol Haemost Thromb 35(3-4):314. [CrossRef]

Lipoprotein (a) metabolism estimated by nonsteady-state kinetics
Klaus G. Parhofer, Thomas Demant, Michael M. Ritter, H. Christian Geiss, Markus Donner, Peter Schwandt
Lipid 34(4):325. [CrossRef]

In vivo turnover study demonstrates diminished clearance of lipoprotein(a) in hemodialysis patients
M E Frischmann, F Kronenberg, E Trenkwalder, J R Schaefer, H Schweer, B Dieplinger, P Koenig, K Ikewaki, H Dieplinger
Kidney Int 71(10):1036. [CrossRef]